Review of the proliferation ihibitor everolimus

Expert Opinion on Investigational Drugs

Volumn 11, Issue 12, 2002, Pages 1845-1857

  Nashan, Björn ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute rejection; Certican ; Chronic rejection; Cyclosporine; Cyclosporine sparing; Cytomegalovitus; Everolimus; Mycophenolate mofetil; Transplantation; Vascular remodelling

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A; DACLIZUMAB; ERYTHROMYCIN; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; ISOENZYME; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOPROTEIN PHOSPHATASE; PREDNISOLONE; RAPAMYCIN; SERINE; TACROLIMUS; THREONINE; DRUG DERIVATIVE;

ACUTE GRAFT REJECTION; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; MICROEMULSION; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; RECIPIENT; REVIEW; THROMBOCYTOPENIA; ANIMAL; DRUG INTERACTION; GRAFT REJECTION; LIVER TRANSPLANTATION;

ANIMALS; DRUG INTERACTIONS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; SIROLIMUS;

EID: 0036912410     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.12.1845     Document Type: Review

References (65)

1. HUSSAR DA: New drugs of 1999. J. Am. Pharmaceut. Soc. (2000) 40:181-221.
2. SEDRANI R, COTTENS S, KALLEN J, SCHULER W: Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant. Proc. (1998) 30:2192-2194.
3. HUMAR A, PAYNE WD, SUTHERLAND DE, MATAS AJ: Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation (2000) 69:2357-2360.
4. PAUL LC: Chronic allograft nephropathy: an update. Kidney Int. (1999) 56:783-793.
5. MONACO AP, BURKE JF Jr, FERGUSON RM et al.: Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am. J. Kidney. Dis. (1999) 33(1):150-160.
6. MEIER-KRIESCHE HU, OJO AO, HANSON JA et al.: Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation (2000) 70:1098-1100.
7. HUMAR A, KERR S, GILLINGHAM KJ, MATAS AJ: Features of acute rejection that increase risk for chronic rejection. Transplantation (1999) 68:1200-1203.
8. TEJANI A, SULLIVAN EK: The impact of acute rejection on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr. Transplant. (2000) 4:107-111.
9. MATAS AJ, HUMAR A, PAYNE WD et al.: Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann. Surg. (1999) 230:493-500.
10. HUMAR A, GILLINGHAM KJ, PAYNE WD, DUNN DL, SUTHERLAND DER, MATAS AJ: Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation (1999) 68:1879-1883.
11. FRENCH CG, BELITSKY P, LAWEN JG: Progress in renal transplantation. Can. J. Urol. (2000) 7:1030-1037.
12. DE MATTOS AM, OLYAEI AJ, BENNETT WM: Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am. J. Kidney Dis. (2000) 35:333-346.
13. BELITSKY P: Neoral use in the renal transplant recipient. Transplant. Proc. (2000) 32(Suppl. 3A):10S-19S.
14. SCHULER W, SEDRANI R, COTTENS S et al.: SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation (1997) 64:36-42.
15. BÖHLER T, WAISER J, BUDDE K et al.: The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant. Proc. (1998) 30:2195-2197.
16. SCHUURMAN HJ, COTTENS S, FUCHS S et al.: SDZ RAD, a new rapamycin derivative. Transplantation (1997) 64:32-35.
17. KELLY P, GRUBER SA, BEHBOD F, KAHAN BD: Sirolimus, a new potent immunosuppressive agent. Pharmacotherapy (1997) 17:1148-1156.
18. 1 progression. J. Biol. Chem. (1999) 274:4266-4272.
19. SCHUURMAN HJ, RINGERS J, SCHULER W, SLINGERLAND W, JONKER M: Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation (2000) 69:737-742.
20. SCHUURMAN HJ, SCHULER W, RINGERS J, JONKER M: The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant. Proc. (1998) 30:2198-2199.
21. YAMASHITA K, HASHIMOTO T, KOBAYASHI T, NAN H, FURUKAWA H, TODO S: Effect of new immunosuppressants RAD and FTY720 on rat liver transplantation. 2001: A Transplant Odyssey. The Future Is Here. Istanbul, Turkey (2001):FC3.8.
22. HAUSEN B, BOEKE K, BERRY GJ, SEGARRA IT, CHRISTIANS U, MORRIS RE: Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J. Heart Lung Transplant. (1999) 18:150-159.
23. HAUSEN B, BOEKE K, BERRY GJ et al.: Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients. Transplantation (1999) 67:956-962.
24. HAUSEN B, BOEKE K, BERRY GJ, CHRISTIANS U, SCHÜLER W, MORRIS RE: Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD. Ann. Thorac. Surg. (2000) 69:904-909.
25. HAUSEN B, IKONEN T, BRIFFA N et al.: Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation (2000) 69:76-86.
26. SERKOVA N, HAUSEN B, BERRY GJ et al.: Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J. Pharmacol. Exp. Ther. (2000) 294:323-332.
27. HAUSEN B, GUMMERT J, BERRY GJ et al.: Prevention of acute allograft rejection in nonhuman primate lung transplant recipients. Transplantation (2000) 69:488-496.
28. VIKLICKY O, ZOU H, MÜLLER V, LACHA J, SZABÓ A, HEEMANN U: SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation (2000) 69:497-502.
29. COLE OJ, SHEHATA M, RIGG KM: Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant. Proc. (1998) 30:2200-2203.
30. SCHUURMAN HJ, PALLY C, WECKBECKER G, SCHULER W, BRUNS C: SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant. Proc. (1999) 31:1024-1025.
31. SALMINEN US, MAASILTA PK, TASKINEN EI, ALHO HS, IKONENE TS, HARJULA ALJ: Prevention of small airway obliteration in a swine heterotropic lung allograft model. J. Heart Lung Transplant. (2000) 19:193-206.
32. MAJEWSKI M, KORECKA M, KOSSEV P et al.: The immunosuppressive macrolide RAD inhibits growth of the human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl. Acad. Sci. USA (2000) 97:4285-4290.
33. SERKOVA N, LITT L, LEIBFRITZ D et al.: The novel immunosuppressant SDZ-RAD protects brain slices from cyclosporine-induced reduction of high-energy phosphates. Br. J. Pharmacol. (2000) 129:485-492.
34. QUESNIAUX VFJ, MENNINGER K, KUNKLER A et al.: The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgous monkeys when given alone, with cyclosporine Neoral® or with RAD. Transplant Immunol. (2000) 8:177-187.
35. NIKLOVA Z, HOF A, BAUMLIN Y, HOF RP: The peripheral lymphocyte count predicts graft survival in DA to Lewis heart transplantation treated with FTY720 and SDZ RAD. Transplant Immunol. (2000) 8:115-124.
36. BRINKMANN V, ALBERT R, WILT C, KRISTOFIC C, FENG S, HOF R: FTY720, a novel transplantation drug that modulates lymphocyte migratory responses: potential role of lysophospholipid receptors. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):S12.1.
37. KIRCHNER GI, WINKLER M, MUELLER L et al.: Pharmacokinetics of SDZ RAD and cyclosporine including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br. J. Clin. Pharmacol. (2000) 50:449-454.
38. KAHAN BD, WONG RL, CARTER C et al.: A Phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-treated renal transplant recipients. Transplantation (1999) 68:1100-1106.
39. NEUMAYER HH, PARADIS K, KORN A et al.: Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br. J. Clin. Pharmacol (1999) 48:694-703.
40. KOVARIK JM, KAHAN BD, KAPLAN B et al.: Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin. Pharmacol. Ther. (2001) 69:48-56.
41. KOVARIK JM, HSU CH, MCMAHON L, BERTHIER S, RORDORF C: Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin. Pharmacol. Ther. (2001) 70:247-254.
42. KOVARIK JM, SABIA H, ROUILLY M et al.: Influence of renal and hepatic impairment on everolimus pharmacokinetics: Are dose adjustments necessary? Am. J. Transplant. (2001) 1(Suppl. 1):989.
43. LEVY GA, GRANT D, PARADIS K, CAMPESTRINI J, SMITH T, KOVARIK JM: Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation (2001) 71:160-163.
44. LEVY G: A one-year, multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding study to evaluate the safety, tolerability, and pharmacokinetics of RAD in de novo liver transplant recipients. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):S8.2.
45. KIRCHNER GI, VIDAL C, WINKLER M et al.: LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites, in human blood. Ther. Drug Monitor. (1999) 21:116-122.
46. VIDAL C, KIRCHNER GI, WUNSCH G, SEWING KF: Automated simultaneous quantification of the immunosuppressants 40-0-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospraymass spectrometric detection. Clin. Chem. (1998) 44:1275-1282.
47. VIDAL C, KIRCHNER GI, SEWING KF: Structural elucidation by electrospray mass spectrometry: An approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. J. Am. Soc. Mass Spectrom. (1998) 9:1267-1274.
48. KOVARIK JM, KALBAG J, FIGUEIREDO J, ROUILLY M, O'BANNON LF, RORDORF C: Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J. Clin. Pharmacol. (2002) 42: 95-99.
49. KOVARIK JM, HARTMANN S, FIGUEIREDO J et al.: Rifampin (a P450 enzyme-inducer) significantly increases the clearance of everolimus: implications for coadministration. Am. J. Transplant. (2001) 1(Suppl. 1):643.
50. KAHAN BD, KAPLAN B, LORBER MI, WINKLER M, CAMBON N, BOGER RS: RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation (2001) 71:1400-1406.
51. VÍTKO Š, MARGREITER R. WEIMAR W et al.: Everolimus (Certican™) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation (In press).
52. TEDESCO-SILVA H, KAPLAN B, MENDEZ R et al.: Certican™ (RAD, everolimus) is complementary with Neoral in preventing organ rejection as part of triple therapy in de novo renal transplant recipients. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):S18.5.
53. MOURAD G, NASHAN B, CURTIS J et al.: Certican (RAD; everolimus), the proliferation signal inhibitor, is complementary with a reduced dose Neoral based quadruple immunosuppressive regimen. 2001: A Transplant Odyssey. The future is here. Istanbul, Turkey (2001):S18.1.
54. ETTENGER R. Certican™ in combination with Neoral® in pediatric de novo renal transplant patients: interim analysis at 3 months demonstrated no occurrence of biopsy-proven acute rejection, graft loss or death. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):D6.2a.
55. KOVARIK JM, KAPLAN B, TADESCO SILVA H et al.: Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation (2002) 73:920-925.
56. CURTIS J, NASHAN B, KOVARIK JM et al.: RAD (everolimus) pharmacokinetics are unaltered with full-dose versus reduced-dose cyclosporine. Am. J. Transplant. (2001) 1(Suppl. 1):651.
57. PONTICELLI C, GLOTZ D, ZIALTEL V et al.: Certican™ with reduced dose Neoral results in a significantly higher GFR in de novo renal transplant recipients over the first 12 months compared to Certican-full dose Neoral as assessed by isohexol clearance. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):S18.2.
58. EISEN H, DORENT R, MANCINI D et al.: Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis. J. Heart Lung Transplant. (2002) 21:55.
59. KAHAN B: FY720 in combination with RAD: a calcineurin antagonist-free maintenance immunosuppression strategy. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):S12.5.
60. JOHNSON RW, KREIS H, OBERBAUER R, BRATTSTROM C, CLAESSON K, ERIS J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 72:777-786.
61. PRIMMETT DR, LEVINE M, KOVARIK JM, MUELLER EA, KEOWN PA: Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther. Drug Monitor. (1998) 20:276-283.
62. CANTAROVICH M, BESNER JG, BARKUN JS, ELSTEIN E, LOERTSCHER R:Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin. Transplant. (1998) 12:243-249.
63. 2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral formulation. BioDrugs (2001) 15:279-290.
64. 2 monitoring. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):PII.3.
65. 2 in the de novo and maintenance liver transplant. 2001: A Transplant Odyssey. The Future is Here. Istanbul, Turkey (2001):PII.4.